TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE CREAM

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); CLOTRIMAZOLE

থেকে পাওয়া:

TARO PHARMACEUTICALS INC

এটিসি কোড:

D01AC20

INN (আন্তর্জাতিক নাম):

IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS

ডোজ:

0.05%; 1%

ফার্মাসিউটিকাল ফর্ম:

CREAM

রচনা:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%; CLOTRIMAZOLE 1%

প্রশাসন রুট:

TOPICAL

প্যাকেজ ইউনিট:

15G/50G

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANTI-INFLAMMATORY AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0216399001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2020-02-19

পণ্য বৈশিষ্ট্য

_Page 1 of 17_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE
Clotrimazole and Betamethasone Dipropionate Cream, USP
1% w/w clotrimazole / 0.05% w/w betamethasone (as betamethasone
dipropionate)
Topical Antifungal and Corticosteroid Agent
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
March 29, 2021
Brampton, ON
L6T 1C1
Submission
Control Number: 246369
_Page 2 of 17_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
1
INDICATIONS
..................................................................................................................3
1.1
Pediatrics....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS
.................................................................................................3
3
DOSAGE AND ADMINISTRATION
.............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Recommended Dose and Dosage Adjustment
...........................................................3
3.3
Administration
...........................................................................................................4
4
MISSED DOSE
..................................................................................................................4
5
OVERDOSAGE
.................................................................................................................4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................5
7
WARNINGS AND PRECAUTIONS
...............................................................................5
7.1
Special Populations
...................................................